Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
AEX4089DC1 Oral Squamous Cell Carcinoma	MacroGenics	P2	CCC (53)
AEX4089DC1 Small Cell Carcinoma	MacroGenics	P2	CCC (53)
Anetumab Ravtansine Fallopian Tube Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Anetumab Ravtansine Fallopian Tube Serous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Anetumab Ravtansine Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Anetumab Ravtansine Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Anetumab Ravtansine Fallopian Tube Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Anetumab Ravtansine Ovarian Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Anetumab Ravtansine Primary Peritoneal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Anetumab Ravtansine Primary Peritoneal Serous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE Chemotherapy-Induced Toxicity	Shanghai Zhongshan Hospital	P2	CCC (53)
Anti-EGFR Antibody-drug Conjugate MRG003 Hepatocellular Carcinoma	Fudan University	P2	CCC (53)
ARX 788 Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
ARX 788 Hormone Receptor Negative Tumor	QuantumLeap Healthcare Collaborative	P2	CCC (53)
ARX 788 Hormone Receptor Positive Tumor	QuantumLeap Healthcare Collaborative	P2	CCC (53)
b1: trop2 adc Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Brentuximab Vedotin ALK-Negative Anaplastic Large Cell Lymphoma	City of Hope Medical Center	P2	CCC (53)
Brentuximab Vedotin Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly	The First Affiliated Hospital with Nanjing Medical University	P2	CCC (53)
Brentuximab Vedotin Hematologic Disorder	M.D. Anderson Cancer Center	P2	CCC (53)
Brentuximab Vedotin Infectious Mononucleosis	Yale University	P2	CCC (53)
Cetuximab Sarotalocan Non-Small Cell Lung Carcinoma	Roswell Park Cancer Institute	P2	CCC (53)
Cetuximab Sarotalocan Lung Cancer	Roswell Park Cancer Institute	P2	CCC (53)
Datopotamab Deruxtecan Advanced or Metastatic Solid Tumour	Jules Bordet Institute	P2	CCC (53)
Datopotamab Deruxtecan Alopecia	Jules Bordet Institute	P2	CCC (53)
Datopotamab Deruxtecan Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)

Showing 301 to 325 of 1,027 assets

PreviousPage 13 of 42Next